Schizophrenia Clinical Trials in Bellevue, Washington

5 studies are recruiting for schizophrenia in Bellevue, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Brenipatide in Adult Participants With Schizophrenia

    The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

    Stage
    Phase 2
    Ages
    18 to 55
    Site
    Northwest Clinical Research Center, Bellevue, Washington
    Locations
    103 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07410507 on ClinicalTrials.gov

  2. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

    Stage
    Phase 3
    Ages
    5 to 17
    Site
    Northwest Clinical Research Center, Bellevue, Washington
    Locations
    64 in total
    Run by
    Intra-Cellular Therapies, Inc.

    See if you can join NCT06229210 on ClinicalTrials.gov

  3. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, Bellevue, Washington
    Locations
    57 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

  4. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, Bellevue, Washington
    Locations
    20 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07227818 on ClinicalTrials.gov

  5. Randomized Withdrawal Study in Patients With Schizophrenia

    The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Vanda Investigational Site, Bellevue, Washington
    Locations
    22 in total
    Run by
    Vanda Pharmaceuticals

    See if you can join NCT06961968 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.